Institute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor-Stern Kai 7, Frankfurt 60590, Germany.
Institute of Clinical Pharmacology, Faculty of Medicine, Goethe University Frankfurt, Theodor-Stern Kai 7, Frankfurt 60590, Germany.
Prog Lipid Res. 2019 Apr;74:160-185. doi: 10.1016/j.plipres.2019.04.002. Epub 2019 Apr 4.
Drug resistance is one major reason for failure of cancer therapy. In the past 10 years, evidence emerged showing that ceramides of specific chain length, generated by six different ceramide synthases (CerS), are deregulated in different cancer types thereby influencing chemosensitivity. In this review we sum up the cellular mechanisms regulated by CerS and the respective ceramides of specific chain length contributing to chemoresistance and how we can interfere with these mechanisms to overcome drug resistance by targeting CerS. We compile an overview of the different cellular effects influenced by CerS in dependency of the used drug and cancer type. Finally, the potential of CerS as new drug targets in chemotherapy or as biomarkers for the prediction of therapeutic response rates is discussed.
耐药性是癌症治疗失败的一个主要原因。在过去的 10 年中,有证据表明,六种不同的神经酰胺合酶(CerS)产生的特定链长的神经酰胺在不同的癌症类型中失调,从而影响化疗敏感性。在这篇综述中,我们总结了 CerS 调节的细胞机制和特定链长的神经酰胺,这些神经酰胺有助于化疗耐药性,以及我们如何通过靶向 CerS 来干扰这些机制以克服耐药性。我们综述了不同的细胞效应,这些效应取决于所使用的药物和癌症类型。最后,讨论了 CerS 作为化疗新的药物靶点或作为预测治疗反应率的生物标志物的潜力。